Clinical Trial Update: Nefecon and Ambrisentan in IgA Nephropathy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating Nefecon and Ambrisentan for IgA nephropathy and related kidney disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Iga Nephropathy

Drugs mentioned

• Ambrisentan (Ambrisentan)
• Nefecon (nefecon)

Snippet

Sponsor: The First Hospital of Jilin University | Conditions: IgA Nephropathy, Chronic Kidney Disease | Phase 4 | Status: RECRUITING